OncoMatch/Clinical Trials/NCT06415669
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Is NCT06415669 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Paclitaxel for and Adebrelimab for gastric/gastroesophageal junction adenocarcinoma.
Treatment: Paclitaxel for · Adebrelimab · Apatinib mesylate — To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Excluded: HER2 (ERBB2) overexpression or amplification
HER2-positive patients [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: immunotherapy — first-line
Patients who have received at least first-line immunotherapy progression or intolerance in the past
Cannot have received: taxane (paclitaxel)
Exception: Neoadjuvant or adjuvant taxoid drugs allowed if disease progression >6 months after last chemotherapy
Patients who have previously received paclitaxel chemotherapy; Patients with neoadjuvant or adjuvant treatment with taxoid drugs and disease progression more than 6 months after the last chemotherapy were excluded
Lab requirements
Blood counts
ANC ≥1.5x10^9/L (no G-CSF in past 14 days); Platelets ≥100x10^9/L (no transfusion in past 14 days); Hemoglobin >90g/L (no transfusion or erythropoietin in past 14 days)
Kidney function
Serum creatinine ≤1.5× ULN and creatinine clearance ≥40 ml/min
Liver function
Total bilirubin ≤1.5× ULN; AST/ALT ≤2.5× ULN (≤5× ULN with liver metastasis)
Cardiac function
Myocardial enzyme profile within normal range (unless abnormality not clinically significant); Good coagulation function (INR or PT ≤1.5× ULN)
The major organs function normally and meet the following criteria...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06415669 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane disqualifies patients from enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression or amplification is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages